References
- Janigan D T. Cytoplasmic bodies in the adrenal cortex of patients treated with spironolactone. Lancet 1963; 1: 850–2
- Jenis E H, Hettzog R W. Effect of spironolactone on the zona glomerulosa of the adrenal gland. Arch Pathol 1969; 88: 530–9
- Cain D R, Van De Velde R, Shapiro S J. Spironolactone inclusions in an aldosteronoma. Am J Clin Pathol 1974; 61: 412–6
- Shrago S S, Waisman J, Cooper P H. Spironolactone bodies in an adrenal adenoma. Arch Pathol 1975; 99: 416–20
- Conn J W, Hinerman D L. Spironolactone induced inhibition of aldosterone biosynthesis in primary aldosteronism: morphological and functional studies. Metabolism 1977; 26: 1293–307
- Gordon R D, Jackson R V, Strakosch C R. Aldosterone-producing-adenoma: fludrocortisone suppression and left adrenal vein catheterisation in definitive diagnosis and management. Aust NZ J Med 1979; 9: 676–82
- Neville A M, Symington T. Pathology of primary aldosteronism. Cancer 1966; 19: 1854–68
- Kovacs E, Horvath E, Singer W. Fine structure and morphogenesis of spironolactone bodies in the zona glomerulosa of the human adrenal cortex. J Clin Pathol 1973; 26: 949–57
- Kovacs K, Khandekar J D, Szabo S. Effect of cyclophosphamide on the rat adrenal cortex. A light and electron microscopic study. Rev Can Biol 1972; 31: 105–17
- Kovacs K, Horvath E, Szabo S. Cyclophosphamide-induced ultrastructural changes in the corpus luteum of rats. Experientia 1973; 29: 839–40